Trials / Conditions / Staphylococcal Skin Infections

Staphylococcal Skin Infections

22 registered clinical trials studyying Staphylococcal Skin Infections.

Status	Trial	Sponsor	Phase
Completed	Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Susp NCT02814916	AbbVie	Phase 3
Unknown	Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA NCT02566928	Clinical Directors Network	Phase 4
Completed	Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA NCT02582203	Wayne State University	Phase 4
Completed	Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA NCT01419184	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 4
Completed	Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Militar NCT01105767	Henry M. Jackson Foundation for the Advancement of Military Medicine	N/A
Completed	An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults NCT01018641	Pfizer	Phase 1
Completed	Staphylococcus Aureus Decolonization Study NCT00731783	Washington University School of Medicine	N/A
Completed	A Complicated Skin and Soft-tissue Infection Patient Registry NCT00737269	Ortho-McNeil Janssen Scientific Affairs, LLC	—
Completed	Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections NCT00719810	Melinta Therapeutics, Inc.	Phase 2
Completed	Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections NCT01198262	Michael E. DeBakey VA Medical Center	—
Completed	Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections NCT00646958	Melinta Therapeutics, Inc.	Phase 2
Completed	A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years o NCT01026636	Basilea Pharmaceutica	Phase 1
Completed	A Study for Patients With Complicated Skin and Skin Structure Infections NCT00514527	Targanta Therapeutics Corporation	Phase 2
Completed	A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients NCT01026558	Basilea Pharmaceutica	Phase 1
Completed	Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers NCT01026740	Basilea Pharmaceutica	Phase 1
Terminated	First Time in Man Trial for Friulimicin B NCT00492271	MerLion Pharmaceuticals GmbH	Phase 1
Completed	Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease NCT01030731	Basilea Pharmaceutica	Phase 1
Completed	Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates NCT00475930	Henry M. Jackson Foundation for the Advancement of Military Medicine	N/A
Completed	The Natural History of Community-Associated MRSA Infections and Decolonization Strategies NCT00513799	Washington University School of Medicine	N/A
Terminated	Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections NCT00463801	Novartis	Phase 4
Completed	Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections NCT00210899	Basilea Pharmaceutica	Phase 3
Completed	Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections NCT00228982	Basilea Pharmaceutica	Phase 3